Published in J Med Chem on December 02, 1999
Bi- or multifunctional opioid peptide drugs. Life Sci (2009) 1.69
Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS J (2006) 1.46
Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models. Chem Biol Drug Des (2012) 1.14
Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties. J Med Chem (2009) 1.03
Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide. ACS Chem Biol (2011) 1.03
6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem (2006) 1.02
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem (2006) 1.00
The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev (2013) 0.98
Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem (2006) 0.97
Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1). J Med Chem (2005) 0.91
Conformationally constrained opioid ligands: the Dmt-Aba and Dmt-Aia versus Dmt-Tic scaffold. Bioorg Med Chem Lett (2008) 0.89
New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem (2006) 0.83
Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem (2007) 0.83
Molecular Pharmacology of δ-Opioid Receptors. Pharmacol Rev (2016) 0.80
Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph. Pharmacol Biochem Behav (2008) 0.79
Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues. Biopolymers (2014) 0.77
The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice. Psychopharmacology (Berl) (2016) 0.75
2',6'-dimethylphenylalanine: a useful aromatic amino Acid surrogate for tyr or phe residue in opioid peptides. Int J Med Chem (2012) 0.75
A developmental and genetic classification for malformations of cortical development. Neurology (2005) 3.50
Terminology and classification of the cortical dysplasias. Neurology (2004) 2.99
Classification system for malformations of cortical development: update 2001. Neurology (2001) 2.59
Vagal non-adrenergic inhibition of guinea-pig stomach. J Physiol (1971) 2.29
Simplified adaptor for electroelution. Anal Biochem (1971) 2.19
Periventricular heterotopia: phenotypic heterogeneity and correlation with Filamin A mutations. Brain (2006) 2.00
Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol (2000) 1.97
The effect of catecholamines and sympathetic stimulation on the release of acetylcholine from the guinea-pig colon. Br J Pharmacol (1969) 1.81
beta-Lipotropin as a prohormone for the morphinomimetic peptides endorphins and enkephalins. Proc Natl Acad Sci U S A (1976) 1.79
Antimyoclonic effects of alcohol in progressive myoclonus epilepsy. Neurology (1990) 1.78
Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion. Neurology (2008) 1.74
Comparison of tissue transglutaminase-specific antibody assays with established antibody measurements for coeliac disease. J Autoimmun (1999) 1.70
GLUT1 mutations are a rare cause of familial idiopathic generalized epilepsy. Neurology (2012) 1.67
Syndromes of bilateral symmetrical polymicrogyria. AJNR Am J Neuroradiol (2000) 1.66
Congenital bilateral perisylvian syndrome: study of 31 patients. The CBPS Multicenter Collaborative Study. Lancet (1993) 1.65
Surgical resection for intractable epilepsy in "double cortex" syndrome yields inadequate results. Epilepsia (2001) 1.62
Laparoscopic cholecystectomy in the third trimester of pregnancy. Am Surg (1996) 1.60
Protocadherin 19 mutations in girls with infantile-onset epilepsy. Neurology (2010) 1.59
Intestinal perforation as a long-term complication of plug and mesh inguinal hernioplasty: case report. Hernia (2004) 1.58
Prognostic factors of malignant mesothelioma of the pleura. Cancer (1993) 1.58
Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. Neurology (2005) 1.57
Characterization of mutations in the gene doublecortin in patients with double cortex syndrome. Ann Neurol (1999) 1.47
Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br J Pharmacol (2008) 1.46
Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest (1993) 1.46
Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology (2003) 1.45
Allergic vasculitis Gougerot-Ruiter syndrome. Arch Dermatol (1967) 1.44
X-linked malformations of neuronal migration. Neurology (1996) 1.42
A new selective antagonist of the nociceptin receptor. Br J Pharmacol (1998) 1.41
TEM-72, a new extended-spectrum beta-lactamase detected in Proteus mirabilis and Morganella morganii in Italy. Antimicrob Agents Chemother (2000) 1.41
Human lung small-cell carcinoma contains bombesin. Proc Natl Acad Sci U S A (1982) 1.39
Facial hemangioma and cerebral corticovascular dysplasia: a syndrome associated with epilepsy. Neurology (2003) 1.39
Effect of gluten-free diet on bone mineral content in growing patients with celiac disease. Am J Clin Nutr (1993) 1.37
Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem (1997) 1.36
Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol Med (1995) 1.34
Noradrenaline inhibition of acetylcholine release from guinea-pig brain. Eur J Pharmacol (1978) 1.30
Radioautographic localization of 125I-atrial natriuretic factor (ANF) in rat tissues. Histochemistry (1985) 1.26
Further evidence for the presence of non-adrenergic inhibitory structures in the guinea-pig colon. Eur J Pharmacol (1968) 1.26
Macroamylasemia attributable to gluten-related amylase autoantibodies: a case report. Pediatrics (2001) 1.24
Presence and bronchomotor activity of protease-activated receptor-2 in guinea pig airways. Am J Respir Crit Care Med (2000) 1.24
Alternative promoter and 5' exon generate a novel Gs alpha mRNA. J Biol Chem (1990) 1.23
Dose-related hemodynamic and renal effects of dopamine in congestive heart failure. Am Heart J (1974) 1.22
Viscosity-density gradient for purification of foot-and-mouth disease virus. Arch Gesamte Virusforsch (1972) 1.22
Sexually transmitted diseases and risk of HIV infection. Acta Derm Venereol (1996) 1.22
Band heterotopia: correlation of outcome with magnetic resonance imaging parameters. Ann Neurol (1994) 1.22
Clinical and molecular characteristics of 1qter microdeletion syndrome: delineating a critical region for corpus callosum agenesis/hypogenesis. J Med Genet (2008) 1.20
Asbestos content of lung tissue, lymph nodes, and pleural plaques from former shipyard workers. Am Rev Respir Dis (1990) 1.20
Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol (2000) 1.18
Familial periventricular heterotopia: missense and distal truncating mutations of the FLN1 gene. Neurology (2002) 1.18
Murine model of accelerated transplant arteriosclerosis. Circ Res (1994) 1.18
Effects of metoclopramide on isolated guinea-pig colon. 2. Interference with ganglionic stimulant drugs. Eur J Pharmacol (1970) 1.16
Intracellular levels of the LIS1 protein correlate with clinical and neuroradiological findings in patients with classical lissencephaly. Ann Neurol (1999) 1.16
Percutaneous endovascular abdominal aortic aneurysm repair: methods and initial outcomes from the first prospective, multicenter trial. J Cardiovasc Surg (Torino) (2011) 1.16
Bowel frequency in healthy children. Acta Paediatr Scand (1989) 1.16
Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth (2009) 1.15
The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer (2000) 1.15
Mutations in the oligophrenin-1 gene (OPHN1) cause X linked congenital cerebellar hypoplasia. J Med Genet (2003) 1.14
Bilateral posterior periventricular nodular heterotopia: a recognizable cortical malformation with a spectrum of associated brain abnormalities. AJNR Am J Neuroradiol (2013) 1.14
Familial perisylvian polymicrogyria: a new familial syndrome of cortical maldevelopment. Ann Neurol (2000) 1.13
Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry (2002) 1.13
A prospective, longitudinal study of the long-term effect of treatment on bone density in children with celiac disease. J Pediatr (2001) 1.13
Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study. J Urol (2001) 1.12
Letter: Cytoplasmic DNA polymerase: polymeric forms and their conversion into an active monomer resembling nuclear DNA polymerase. J Mol Biol (1973) 1.11
Human doublecortin (DCX) and the homologous gene in mouse encode a putative Ca2+-dependent signaling protein which is mutated in human X-linked neuronal migration defects. Hum Mol Genet (1998) 1.09
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.08
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br J Pharmacol (1998) 1.07
Clinical and socio-economic impact of influenza and respiratory syncytial virus infection on healthy children and their households. Clin Microbiol Infect (2005) 1.07
Reduction in myocardial ischemia with nitroglycerin or nitroglycerin plus phenylephrine administered during acute myocardial infarction. N Engl J Med (1975) 1.06
Comparison of the effects of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors. Br J Pharmacol (1999) 1.06
Mast cell binding of neurotensin. I. Iodination of neurotensin and characterization of the interaction of neurotensin with mast cell receptor sites. J Biol Chem (1977) 1.05
Genetic and neuroradiological heterogeneity of double cortex syndrome. Ann Neurol (2000) 1.05
Functional studies of new GLA gene mutations leading to conformational Fabry disease. Biochim Biophys Acta (2009) 1.05
Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity. J Med Chem (1997) 1.05
Increased pulmonary vascular contraction to serotonin after cardiopulmonary bypass: role of cyclooxygenase. J Surg Res (2000) 1.04
Increased proteolytic processing of protein tyrosine phosphatase mu in confluent vascular endothelial cells: the role of PC5, a member of the subtilisin family. Biochemistry (1996) 1.04
Angelman syndrome: correlations between epilepsy phenotypes and genotypes. Ann Neurol (1998) 1.04
Mosaic mutations of the LIS1 gene cause subcortical band heterotopia. Neurology (2003) 1.04
Abnormal corticomuscular and intermuscular coupling in high-frequency rhythmic myoclonus. Brain (2003) 1.04
Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations. Int J Antimicrob Agents (2001) 1.03
The cerebral acetylcholine release in conscious rabbits with semi-permanently implanted epidural cups. Int J Neuropharmacol (1968) 1.03
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med Chem (1998) 1.02
Nociceptin/orphanin FQ receptor ligands. Peptides (2000) 1.02
Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab (2009) 1.02
Nodular vasculitis: immunofluorescent study; 7S gamma-globulin and complement (beta-1c-globulin) in lesions of nodular vasculitis. J Invest Dermatol (1966) 1.01
The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur J Pharmacol (1996) 1.00
In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol (2000) 1.00
Posterior quadrantic dysplasia or hemi-hemimegalencephaly: a characteristic brain malformation. Neurology (2004) 1.00